Google
RLYB Stock Price & Analysis — Rallybio Corp (Healthcare >> Biotechnology)
RLYB FAQ
What is RLYB's P/E ratio?
Rallybio Corp (RLYB) currently trades at a P/E ratio of 5.32.
What is RLYB's ROE?
Rallybio Corp reports a Return on Equity (ROE) of -15.55%.
What is RLYB's dividend yield?
Rallybio Corp offers a dividend yield of 0.00%.
What is RLYB's Quality Score?
Our AI rates RLYB's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RLYB?
Our AI Timing Score for RLYB is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RLYB belong to?
Rallybio Corp is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
RLYB AI Analysis Summary
Our AI summary for RLYB: Rallybio Corp (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 5.32, ROE of -15.55%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 15.93
Price
-0.14
(-0.87%)
Day Change
|
|
|---|
RLYB, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 15.93 |
| PBV / Sector |
1.70 / 5.20
|
| Earning Per Share | -1.46 |
| PE / Sector |
5.32 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
-0.13 / 1.22
|
| Average 1M Daily Value |
0.67 M
GREAT
|
| Average 1W Daily Value |
0.28 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:25 |
| Symbol | RLYB |
| Name | RALLYBIO CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 85.28 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 234 Church Street, New Haven, CT, United States, 06510
Phone: 203 859 3820
Website: https://www.rallybio.com
Sector: Healthcare >> Biotechnology
Description: Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap